Keith Dawkins - Boston Scientific President
| BSX Stock | USD 67.42 0.54 0.79% |
President
Dr. Keith D. Dawkins, M.D. is Global Chief Medical Officer, Executive Vice President of the Company. He was Senior Vice President and Chief Medical Officer of our Cardiology, Rhythm and Vascular Group. From 2008 until May 2010, he was our Senior Vice President and Associate Chief Medical Officer of our Cardiovascular business. Prior to joining Boston Scientific in 2008, Dr. Dawkins was a practicing interventional cardiologist for more than 20 years in England. He has earned a series of clinical, research and academic distinctions, including a PostDoctoral Research Fellowship at Stanford University as a Fulbright Scholar. He served as President of the British Cardiovascular Intervention Society, and held numerous appointments on hospital, regional and national committees, including the National Institute for Health and Clinical Excellence. He was an author on more than 750 academic publications and presentations on a variety of cardiac topics. Dr. Dawkins was educated at London University and Guys Hospital, earning a First Class Honors degree in Pathology. He trained in cardiology at Oxford and at the Brompton St. George Hospital in London. since 2012.
| Age | 65 |
| Tenure | 12 years |
| Address | 300 Boston Scientific Way, Marlborough, MA, United States, 01752-1234 |
| Phone | 508 683 4000 |
| Web | https://www.bostonscientific.com |
Boston Scientific Management Efficiency
The company has Return on Asset of 0.0447 % which means that on every $100 spent on assets, it made $0.0447 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.0858 %, implying that it generated $0.0858 on every 100 dollars invested. Boston Scientific's management efficiency ratios could be used to measure how well Boston Scientific manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Boston Scientific's Return On Tangible Assets are fairly stable compared to the past year. Return On Capital Employed is likely to rise to 0.14 in 2024, whereas Return On Equity is likely to drop 0.06 in 2024. At this time, Boston Scientific's Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 30.1 B in 2024, whereas Total Current Assets are likely to drop slightly above 3.3 B in 2024.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Andrew Thomson | Thermo Fisher Scientific | 49 | |
| Aimee Hoyt | Illumina | 47 | |
| Alan Malus | Thermo Fisher Scientific | 55 | |
| David Terricciano | Waters | 61 | |
| Mark Stevenson | Thermo Fisher Scientific | 57 | |
| Emily Hickey | Charles River Laboratories | N/A | |
| Robert Carson | Waters | 46 | |
| Elizabeth Rae | Waters | 60 | |
| Sherry Buck | Waters | 55 | |
| Tristan Orpin | Illumina | 49 | |
| Mostafa Ronaghi | Illumina | 49 | |
| Alicia Rodriguez | Agilent Technologies | N/A | |
| Marcel Roche | Guardant Health | N/A | |
| Nancy Gillett | Charles River Laboratories | 58 | |
| Rohit Khanna | Waters | 58 | |
| Gregory Herrema | Thermo Fisher Scientific | 52 | |
| Mark Doak | Agilent Technologies | 63 | |
| Michael Harrington | Waters | 59 | |
| Mark Oene | Illumina | 45 | |
| Michael Tang | Agilent Technologies | 50 | |
| Sam Samad | Illumina | 48 | |
Management Performance
| Return On Equity | 0.0858 | ||||
| Return On Asset | 0.0447 |
Boston Scientific Corp Leadership Team
Elected by the shareholders, the Boston Scientific's board of directors comprises two types of representatives: Boston Scientific inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Boston. The board's role is to monitor Boston Scientific's management team and ensure that shareholders' interests are well served. Boston Scientific's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Boston Scientific's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Edward Ludwig, Lead Independent Director | ||
| Donna James, Independent Director | ||
| Stephen MacMillan, Independent Director | ||
| Michael Mahoney, Chairman of the Board, President, Chief Executive Officer | ||
| Emily Woodworth, Global VP | ||
| Kevin Ballinger, Executive Vice President and Global President - Interventional Cardiology | ||
| Desiree RallsMorrison, Senior Vice President General Counsel, Corporate Secretary | ||
| Keith Dawkins, Global Chief Medical Officer, Executive Vice President | ||
| Maulik Nanavaty, Senior Vice President and President - Neuromodulation | ||
| Ian Meredith, Executive Vice President Global Chief Medical Officer | ||
| David Pierce, Executive Vice President and President, MedSurg and President - Endoscopy | ||
| Supratim Bose, Executive VP and President of Asia-Pac, Middle East and Africa | ||
| Ellen Zane, Independent Director | ||
| Joseph Fitzgerald, Executive Vice President, President, Interventional Cardiology | ||
| Warren Wang, Senior Vice President and President - Asia Pacific | ||
| Timothy Pratt, Chief Admin. Officer, Executive VP, General Counsel and Secretary | ||
| Eric Thepaut, Executive Vice President and President - Europe, Middle East and Africa | ||
| Daniel Brennan, CFO, Principal Accounting Officer and Executive VP | ||
| Kristina Johnson, Independent Director | ||
| Nelda Connors, Independent Director | ||
| Wendy Carruthers, Executive Vice President - Human Resources | ||
| Peter Nicholas, Co-Founder and Chairman of The Board | ||
| Jodi Eddy, Senior Vice President and Chief Information and Digital Officer | ||
| Catherine Jennings, VP Interventions | ||
| John Sorenson, Senior Vice President - Manufacturing and Supply Chain | ||
| Arthur Butcher, Executive Vice President and President, Asia Pacific | ||
| Edward Mackey, Executive Vice President - Global Operations | ||
| Ernest Mario, Independent Director | ||
| Karen Prange, Senior Vice President and President - Urology & Women's Health | ||
| Scott Olson, Senior Vice President, President - Cardiac Rhythm Management and Diagnostics | ||
| Vance Brown, Senior Vice President General Counsel, Corporate Secretary | ||
| N Nicholas, Independent Director | ||
| Charles Dockendorff, Independent Director | ||
| Mary Moynihan, Senior Officer | ||
| John Sununu, Independent Director | ||
| Michael Phalen, Executive Vice President and President - MedSurg | ||
| Jeffrey Mirviss, Executive Vice President and President - Peripheral Interventions | ||
| Yoshiaki Fujimori, Independent Director | ||
| David Wichmann, Independent Director | ||
| David Roux, Independent Director | ||
| Susan Lisa, VP, Investor Relations | ||
| Jonathan Monson, Chief Accounting Officer, Vice President Global Controller | ||
| Meghan Scanlon, Senior Vice President and President - Urology and Pelvic Health |
Boston Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Boston Scientific a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0858 | ||||
| Return On Asset | 0.0447 | ||||
| Profit Margin | 0.11 % | ||||
| Operating Margin | 0.17 % | ||||
| Current Valuation | 108.89 B | ||||
| Shares Outstanding | 1.47 B | ||||
| Shares Owned By Insiders | 0.19 % | ||||
| Shares Owned By Institutions | 93.65 % | ||||
| Number Of Shares Shorted | 12.43 M | ||||
| Price To Earning | 107.05 X |
Pair Trading with Boston Scientific
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Boston Scientific position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Boston Scientific will appreciate offsetting losses from the drop in the long position's value.Moving together with Boston Stock
| 0.8 | ELMD | Electromed | PairCorr |
| 0.76 | FEMY | Femasys Financial Report 9th of May 2024 | PairCorr |
Moving against Boston Stock
| 0.89 | IVP | Inspire Veterinary | PairCorr |
| 0.82 | EMBC | Embecta Corp Financial Report 10th of May 2024 | PairCorr |
| 0.72 | TFX | Teleflex Incorporated Financial Report 2nd of May 2024 | PairCorr |
| 0.51 | DYNT | Dynatronics Financial Report 9th of May 2024 | PairCorr |
The ability to find closely correlated positions to Boston Scientific could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Boston Scientific when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Boston Scientific - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Boston Scientific Corp to buy it.
The correlation of Boston Scientific is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Boston Scientific moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Boston Scientific Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Boston Scientific can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Boston Scientific Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Complementary Tools for Boston Stock analysis
When running Boston Scientific's price analysis, check to measure Boston Scientific's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Boston Scientific is operating at the current time. Most of Boston Scientific's value examination focuses on studying past and present price action to predict the probability of Boston Scientific's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Boston Scientific's price. Additionally, you may evaluate how the addition of Boston Scientific to your portfolios can decrease your overall portfolio volatility.
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Equity Valuation Check real value of public entities based on technical and fundamental data |
Is Boston Scientific's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Boston Scientific. If investors know Boston will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Boston Scientific listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 2.856 | Earnings Share 1.07 | Revenue Per Share 9.8 | Quarterly Revenue Growth 0.149 | Return On Assets 0.0447 |
The market value of Boston Scientific Corp is measured differently than its book value, which is the value of Boston that is recorded on the company's balance sheet. Investors also form their own opinion of Boston Scientific's value that differs from its market value or its book value, called intrinsic value, which is Boston Scientific's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Boston Scientific's market value can be influenced by many factors that don't directly affect Boston Scientific's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Boston Scientific's value and its price as these two are different measures arrived at by different means. Investors typically determine if Boston Scientific is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Boston Scientific's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.